Being an investor in small-cap biotechnology stocks has been about as fun as being a diehard Los Angeles Lakers fan over the past six monthsThe overall biotech sector is down some 40% from its highs in JulyAnd small-cap biotechs have borne the brunt of this collapse, with myriad names down 50% to 75% on little more than a shift in sentiment to a c...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.